What one share of Cytek Biosciences holds
We are a leading cell analysis solutions company advancing the next generation of research and clinical tools with our novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells (“Full Spectrum Profiling” or “FSP” technology).
Cytek Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.61 |
|---|---|
| Profit | −$0.63 |
| Capex (buildings and equipment) | $0.05 |
| Free cash flow | −$0.09 |
| Cash and investments | $0.57 |
| Debt | $0.00 |
| Book value | $2.48 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $2.85 | $0.10 | $0.05 | $0.42 | — | −$0.51 |
| 2021 | $1.57 | $0.00 | $0.05 | $0.00 | — | $3.03 |
| 2022 | $1.18 | $0.02 | $0.07 | −$0.16 | — | $3.14 |
| 2023 | $1.43 | −$0.09 | $0.03 | $0.00 | — | $3.01 |
| 2024 | $1.53 | −$0.05 | $0.03 | $0.17 | — | $3.06 |
| 2025 | $1.58 | −$0.52 | $0.03 | −$0.07 | — | $2.66 |
Common questions about Cytek Biosciences
How much does one share of Cytek Biosciences earn?
Over the last 12 months, Cytek Biosciences lost $0.63 for each share on $1.61 of sales.
Does Cytek Biosciences pay a dividend?
Cytek Biosciences didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Cytek Biosciences’s book value per share?
Cytek Biosciences’s book value is $2.48 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Cytek Biosciences have?
Each share of Cytek Biosciences has $0.57 of cash and investments and $0.00 of debt, as of June 30, 2026.
What is Cytek Biosciences’s free cash flow per share?
−$0.09 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Cytek Biosciences bought back shares?
Cytek Biosciences’s share count rose about 292% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.